The National Health Surveillance Agency of Brazil, known as Anvisa, has issued a critical alert regarding the use of weight loss pens intended for obesity and diabetes treatment without proper medical supervision. This warning was prompted by a troubling rise in reports of pancreatitis associated with these medications. Specifically, Anvisa informed the public about the ongoing investigation into six fatalities linked to pancreatitis and more than 200 additional cases of pancreatic issues reported during the use of these products.

The alert encompasses all medications containing active ingredients such as dulaglutide, liraglutide, semaglutide, and tirzepatide, which are the main components in various registered weight loss pens in Brazil. Although it is noted in the product information that pancreatitis is a known risk associated with these drugs, Anvisa expressed concern over the recent surge in cases, indicating that this issue poses significant health risks. The agency emphasizes the importance of using these medications exclusively under the guidance and supervision of healthcare professionals.

This situation raises crucial implications for public health policy in Brazil, particularly concerning the regulation of weight loss medications. As the prevalence of obesity has been an increasing concern worldwide, the rise in adverse effects associated with these popular treatments could lead to stricter regulations and more robust guidelines for their safe use. Anvisa's alert serves as a reminder of the potential dangers of self-medication and the need for informed and supervised healthcare interventions.